Clinical Trial

Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2024 (before its estimated May 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the lot-to lot consistency of three batches of recombinant herpes zoster vaccine (CHO cell) produced on a commercial scale in subjects aged 40 years and older after receiving 2 doses on a 0, 2 month schedule.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-22; most recent amendment 2024-11-18.
Trial Details
NCT Number NCT06654700
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Conditions Herpes Zoster
Enrollment 1,200 participants
Start Date 2024-12-09
Primary Completion 2025-05-01 (estimated)
Study Completion 2025-05-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-20